423 related articles for article (PubMed ID: 8521762)
1. Simvastatin. A reappraisal of its pharmacology and therapeutic efficacy in hypercholesterolaemia.
Plosker GL; McTavish D
Drugs; 1995 Aug; 50(2):334-63. PubMed ID: 8521762
[TBL] [Abstract][Full Text] [Related]
2. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
Lennernäs H; Fager G
Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
[TBL] [Abstract][Full Text] [Related]
3. Comparative efficacy study of atorvastatin vs simvastatin, pravastatin, lovastatin and placebo in type 2 diabetic patients with hypercholesterolaemia.
Gentile S; Turco S; Guarino G; Sasso CF; Amodio M; Magliano P; Salvatore T; Corigliano G; Agrusta M; De Simone G; Gaeta I; Oliviero B; Torella R
Diabetes Obes Metab; 2000 Dec; 2(6):355-62. PubMed ID: 11225965
[TBL] [Abstract][Full Text] [Related]
4. Fluvastatin: a review of its pharmacology and use in the management of hypercholesterolaemia.
Plosker GL; Wagstaff AJ
Drugs; 1996 Mar; 51(3):433-59. PubMed ID: 8882381
[TBL] [Abstract][Full Text] [Related]
5. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia.
Hsu I; Spinler SA; Johnson NE
Ann Pharmacother; 1995; 29(7-8):743-59. PubMed ID: 8520093
[TBL] [Abstract][Full Text] [Related]
6. Atorvastatin: an updated review of its pharmacological properties and use in dyslipidaemia.
Malhotra HS; Goa KL
Drugs; 2001; 61(12):1835-81. PubMed ID: 11693468
[TBL] [Abstract][Full Text] [Related]
7. Simvastatin. A review of its pharmacological properties and therapeutic potential in hypercholesterolaemia.
Todd PA; Goa KL
Drugs; 1990 Oct; 40(4):583-607. PubMed ID: 2083515
[TBL] [Abstract][Full Text] [Related]
8. Benefits and risks of HMG-CoA reductase inhibitors in the prevention of coronary heart disease: a reappraisal.
Pedersen TR; Tobert JA
Drug Saf; 1996 Jan; 14(1):11-24. PubMed ID: 8713485
[TBL] [Abstract][Full Text] [Related]
9. Treating hypercholesterolaemia with HMG CoA reductase inhibitors: a direct comparison of simvastatin and pravastatin.
Lintott CJ; Scott RS; Sutherland WH; Bremer J
Aust N Z J Med; 1993 Aug; 23(4):381-6. PubMed ID: 8240151
[TBL] [Abstract][Full Text] [Related]
10. Treatment of primary hypercholesterolaemia. Short-term efficacy and safety of increasing doses of simvastatin and pravastatin: a double-blind comparative study.
Stalenhoef AF; Lansberg PJ; Kroon AA; Kortmann B; De Haan AF; Stuyt PM; Kastelein JJ
J Intern Med; 1993 Jul; 234(1):77-82. PubMed ID: 8326293
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness analysis of cholesterol-lowering therapies in Spain.
Plans-Rubió P
Am J Cardiovasc Drugs; 2006; 6(3):177-88. PubMed ID: 16780391
[TBL] [Abstract][Full Text] [Related]
12. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study).
Jones P; Kafonek S; Laurora I; Hunninghake D
Am J Cardiol; 1998 Mar; 81(5):582-7. PubMed ID: 9514454
[TBL] [Abstract][Full Text] [Related]
13. Atorvastatin. A review of its pharmacology and therapeutic potential in the management of hyperlipidaemias.
Lea AP; McTavish D
Drugs; 1997 May; 53(5):828-47. PubMed ID: 9129869
[TBL] [Abstract][Full Text] [Related]
14. Simvastatin compared to fluvastatin in the reduction of serum lipids and apolipoproteins in patients with ischaemic heart disease and moderate hypercholesterolaemia.
Sigurdsson G; Haraldsdottir SO; Melberg TH; Tikkanen MJ; Miettinen TE; Kristianson KJ
Acta Cardiol; 1998; 53(1):7-14. PubMed ID: 9638964
[TBL] [Abstract][Full Text] [Related]
15. HMG CoA reductase inhibitors as lipid-lowering agents: five years experience with lovastatin and an appraisal of simvastatin and pravastatin.
Maher VM; Thompson GR
Q J Med; 1990 Feb; 74(274):165-75. PubMed ID: 2111917
[TBL] [Abstract][Full Text] [Related]
16. Effects of simvastatin and probucol in hypercholesterolemia (Simvastatin Multicenter Study Group II).
Pietro DA; Alexander S; Mantell G; Staggers JE; Cook TJ
Am J Cardiol; 1989 Mar; 63(11):682-6. PubMed ID: 2646895
[TBL] [Abstract][Full Text] [Related]
17. Cerivastatin: a review of its pharmacological properties and therapeutic efficacy in the management of hypercholesterolaemia.
Plosker GL; Dunn CI; Figgitt DP
Drugs; 2000 Nov; 60(5):1179-206. PubMed ID: 11129127
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors in the treatment of patients with hypercholesterolemia: a meta-analysis of clinical trials.
Kong SX; Crawford SY; Gandhi SK; Seeger JD; Schumock GT; Lam NP; Stubbings J; Schoen MD
Clin Ther; 1997; 19(4):778-97. PubMed ID: 9377621
[TBL] [Abstract][Full Text] [Related]
19. Interactions with hydroxymethylglutaryl-coenzyme A reductase inhibitors.
Garnett WR
Am J Health Syst Pharm; 1995 Aug; 52(15):1639-45. PubMed ID: 7583826
[TBL] [Abstract][Full Text] [Related]
20. Comparisons of effects of statins (atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin) on fasting and postprandial lipoproteins in patients with coronary heart disease versus control subjects.
Schaefer EJ; McNamara JR; Tayler T; Daly JA; Gleason JL; Seman LJ; Ferrari A; Rubenstein JJ
Am J Cardiol; 2004 Jan; 93(1):31-9. PubMed ID: 14697462
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
